The National Institute for Health and Care Excellence (NICE) recommends a significant shift in type 2 diabetes treatment towards personalized care. The move would enhance access to newer medications, particularly SGLT-2 inhibitors, which lower blood sugar and protect heart and kidney health. This approach could prevent severe complications and save thousands of lives. Approximately 4.6 million people in the UK are affected by diabetes, costing the NHS considerable resources. Currently, only a fraction of patients with cardiovascular disease and type 2 diabetes benefit from the recommended treatments, highlighting disparities in access.
NICE recommends prioritizing personalized treatment for type 2 diabetes and expanding access to SGLT-2 inhibitors to prevent complications and save lives.
With 4.6 million diagnosed, including 90% with type 2 diabetes, the NHS spends 10% of its budget treating diabetes-related complications.
Collection
[
|
...
]